|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PPP2R5A |
Gene summary for PPP2R5A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PPP2R5A | Gene ID | 5525 |
| Gene name | protein phosphatase 2 regulatory subunit B'alpha | |
| Gene Alias | B56A | |
| Cytomap | 1q32.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q15172 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5525 | PPP2R5A | LZE2T | Human | Esophagus | ESCC | 6.06e-11 | 5.93e-01 | 0.082 |
| 5525 | PPP2R5A | LZE4T | Human | Esophagus | ESCC | 1.15e-11 | 2.27e-01 | 0.0811 |
| 5525 | PPP2R5A | LZE8T | Human | Esophagus | ESCC | 2.47e-02 | 1.14e-02 | 0.067 |
| 5525 | PPP2R5A | LZE20T | Human | Esophagus | ESCC | 1.22e-03 | 3.11e-02 | 0.0662 |
| 5525 | PPP2R5A | LZE24T | Human | Esophagus | ESCC | 6.45e-10 | 2.35e-01 | 0.0596 |
| 5525 | PPP2R5A | LZE21T | Human | Esophagus | ESCC | 8.28e-05 | 1.78e-01 | 0.0655 |
| 5525 | PPP2R5A | P2T-E | Human | Esophagus | ESCC | 3.36e-12 | 1.63e-01 | 0.1177 |
| 5525 | PPP2R5A | P4T-E | Human | Esophagus | ESCC | 4.81e-06 | 9.09e-02 | 0.1323 |
| 5525 | PPP2R5A | P5T-E | Human | Esophagus | ESCC | 3.86e-09 | 2.34e-01 | 0.1327 |
| 5525 | PPP2R5A | P8T-E | Human | Esophagus | ESCC | 2.39e-13 | 1.35e-01 | 0.0889 |
| 5525 | PPP2R5A | P9T-E | Human | Esophagus | ESCC | 5.14e-11 | 4.13e-01 | 0.1131 |
| 5525 | PPP2R5A | P10T-E | Human | Esophagus | ESCC | 2.49e-15 | 3.11e-01 | 0.116 |
| 5525 | PPP2R5A | P12T-E | Human | Esophagus | ESCC | 1.52e-12 | 1.03e-01 | 0.1122 |
| 5525 | PPP2R5A | P15T-E | Human | Esophagus | ESCC | 2.36e-14 | 4.34e-01 | 0.1149 |
| 5525 | PPP2R5A | P16T-E | Human | Esophagus | ESCC | 4.12e-07 | 2.26e-02 | 0.1153 |
| 5525 | PPP2R5A | P17T-E | Human | Esophagus | ESCC | 1.71e-02 | 1.25e-01 | 0.1278 |
| 5525 | PPP2R5A | P20T-E | Human | Esophagus | ESCC | 5.08e-16 | 2.30e-01 | 0.1124 |
| 5525 | PPP2R5A | P21T-E | Human | Esophagus | ESCC | 2.17e-17 | 2.95e-01 | 0.1617 |
| 5525 | PPP2R5A | P22T-E | Human | Esophagus | ESCC | 6.85e-12 | 2.31e-01 | 0.1236 |
| 5525 | PPP2R5A | P23T-E | Human | Esophagus | ESCC | 7.29e-12 | 2.62e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0072659110 | Esophagus | ESCC | protein localization to plasma membrane | 193/8552 | 284/18723 | 1.95e-14 | 1.03e-12 | 193 |
| GO:199077819 | Esophagus | ESCC | protein localization to cell periphery | 217/8552 | 333/18723 | 4.08e-13 | 1.88e-11 | 217 |
| GO:0010563111 | Esophagus | ESCC | negative regulation of phosphorus metabolic process | 274/8552 | 442/18723 | 2.32e-12 | 9.41e-11 | 274 |
| GO:0045936111 | Esophagus | ESCC | negative regulation of phosphate metabolic process | 273/8552 | 441/18723 | 3.18e-12 | 1.25e-10 | 273 |
| GO:0051348111 | Esophagus | ESCC | negative regulation of transferase activity | 177/8552 | 268/18723 | 1.08e-11 | 4.00e-10 | 177 |
| GO:0042326111 | Esophagus | ESCC | negative regulation of phosphorylation | 237/8552 | 385/18723 | 1.86e-10 | 5.33e-09 | 237 |
| GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
| GO:003367319 | Esophagus | ESCC | negative regulation of kinase activity | 154/8552 | 237/18723 | 1.38e-09 | 3.27e-08 | 154 |
| GO:000647018 | Esophagus | ESCC | protein dephosphorylation | 177/8552 | 281/18723 | 3.13e-09 | 6.72e-08 | 177 |
| GO:190547519 | Esophagus | ESCC | regulation of protein localization to membrane | 117/8552 | 175/18723 | 1.14e-08 | 2.26e-07 | 117 |
| GO:0035304111 | Esophagus | ESCC | regulation of protein dephosphorylation | 66/8552 | 90/18723 | 8.82e-08 | 1.48e-06 | 66 |
| GO:0035303111 | Esophagus | ESCC | regulation of dephosphorylation | 88/8552 | 128/18723 | 1.04e-07 | 1.71e-06 | 88 |
| GO:190437519 | Esophagus | ESCC | regulation of protein localization to cell periphery | 85/8552 | 125/18723 | 3.63e-07 | 5.06e-06 | 85 |
| GO:1903076110 | Esophagus | ESCC | regulation of protein localization to plasma membrane | 72/8552 | 104/18723 | 9.74e-07 | 1.23e-05 | 72 |
| GO:19038289 | Esophagus | ESCC | negative regulation of cellular protein localization | 76/8552 | 117/18723 | 1.97e-05 | 1.72e-04 | 76 |
| GO:00353074 | Esophagus | ESCC | positive regulation of protein dephosphorylation | 31/8552 | 45/18723 | 1.40e-03 | 6.62e-03 | 31 |
| GO:00353066 | Esophagus | ESCC | positive regulation of dephosphorylation | 38/8552 | 59/18723 | 2.86e-03 | 1.21e-02 | 38 |
| GO:19030778 | Esophagus | ESCC | negative regulation of protein localization to plasma membrane | 17/8552 | 24/18723 | 1.13e-02 | 3.81e-02 | 17 |
| GO:00192168 | Esophagus | ESCC | regulation of lipid metabolic process | 172/8552 | 331/18723 | 1.20e-02 | 4.02e-02 | 172 |
| GO:19043765 | Esophagus | ESCC | negative regulation of protein localization to cell periphery | 18/8552 | 26/18723 | 1.32e-02 | 4.31e-02 | 18 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa0301524 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
| hsa0407116 | Esophagus | ESCC | Sphingolipid signaling pathway | 85/4205 | 121/8465 | 3.04e-06 | 1.73e-05 | 8.84e-06 | 85 |
| hsa0415210 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
| hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa041146 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
| hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0516515 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
| hsa0301534 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
| hsa0407117 | Esophagus | ESCC | Sphingolipid signaling pathway | 85/4205 | 121/8465 | 3.04e-06 | 1.73e-05 | 8.84e-06 | 85 |
| hsa0415213 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
| hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa0411411 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
| hsa041528 | Liver | NAFLD | AMPK signaling pathway | 28/1043 | 121/8465 | 6.26e-04 | 9.78e-03 | 7.88e-03 | 28 |
| hsa0415211 | Liver | NAFLD | AMPK signaling pathway | 28/1043 | 121/8465 | 6.26e-04 | 9.78e-03 | 7.88e-03 | 28 |
| hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa0301521 | Liver | HCC | mRNA surveillance pathway | 66/4020 | 97/8465 | 3.16e-05 | 1.88e-04 | 1.04e-04 | 66 |
| hsa0415241 | Liver | HCC | AMPK signaling pathway | 77/4020 | 121/8465 | 2.32e-04 | 1.11e-03 | 6.18e-04 | 77 |
| hsa051652 | Liver | HCC | Human papillomavirus infection | 188/4020 | 331/8465 | 3.34e-04 | 1.49e-03 | 8.29e-04 | 188 |
| Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PPP2R5A | SNV | Missense_Mutation | c.700N>T | p.Leu234Phe | p.L234F | Q15172 | protein_coding | tolerated(0.79) | probably_damaging(0.995) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| PPP2R5A | SNV | Missense_Mutation | rs192765953 | c.545N>A | p.Arg182Gln | p.R182Q | Q15172 | protein_coding | tolerated(0.05) | possibly_damaging(0.523) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
| PPP2R5A | SNV | Missense_Mutation | novel | c.32N>T | p.Ala11Val | p.A11V | Q15172 | protein_coding | tolerated(0.13) | benign(0) | TCGA-VS-A9UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PPP2R5A | SNV | Missense_Mutation | c.638G>A | p.Arg213Gln | p.R213Q | Q15172 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PPP2R5A | SNV | Missense_Mutation | c.818T>C | p.Met273Thr | p.M273T | Q15172 | protein_coding | tolerated(0.71) | benign(0.01) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PPP2R5A | SNV | Missense_Mutation | novel | c.806A>C | p.Lys269Thr | p.K269T | Q15172 | protein_coding | deleterious(0.03) | possibly_damaging(0.771) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| PPP2R5A | SNV | Missense_Mutation | novel | c.697N>C | p.Phe233Leu | p.F233L | Q15172 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-CA-5256-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| PPP2R5A | SNV | Missense_Mutation | c.799G>A | p.Glu267Lys | p.E267K | Q15172 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PPP2R5A | insertion | Frame_Shift_Ins | novel | c.1091_1092insT | p.Gln366SerfsTer12 | p.Q366Sfs*12 | Q15172 | protein_coding | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
| PPP2R5A | deletion | Frame_Shift_Del | c.985delN | p.Leu330Ter | p.L330* | Q15172 | protein_coding | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |